Send to:

Choose Destination
See comment in PubMed Commons below
Endocrinol Metab Clin North Am. 2011 Sep;40(3):615-23, ix. doi: 10.1016/j.ecl.2011.05.005. Epub 2011 Jul 7.

The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

Author information

  • 1Division of Urology, University of Connecticut Health Center, Farmington, CT 06030, USA.


Androgen deprivation therapy (ADT) is an effective means of palliating symptoms of prostate cancer but is associated with significant toxicities that increase with treatment duration. Primary ADT in men with localized disease provides no survival advantage. Neoadjuvant ADT, when combined with external beam radiation, improves survival for men with locally advanced disease. Immediate adjuvant androgen deprivation does not seem to benefit most men undergoing radical prostatectomy. No evidence supports combined androgen blockade or monotherapy with nonsteroidal antiandrogens for locally advanced prostate cancer. ADT with orchiectomy or gonadotropin-releasing hormone agonists or antagonists is standard care for men with metastatic prostate cancer.

Copyright © 2011 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk